Originally Posted by
Dr.Sid
I'm just using current data from here
https://www.covdata.cz/cesko.php infections 65+, which have 80% vaccination rate. So I just take number of vaccinated infections, divide by 4 to correct for 4:1 vaccination ratio in population, and then divide by number by non vaccinated infections. For recent days it's about 60%, to weeks back it was closer to 50%. It would be better to do it with exact age group size and counts of vaccinated and non-vaccinated, but for rough estimate this should be enough.
Israel showed between 60-70% when the last wave started, but it went up
rapidly with introduction of 3rd dose. When the wave peaked, it was above 80%. I used same method, data from here:
https://datadashboard.health.gov.il/...edium=referral
Unfortunately I can't control the page well enough to get to historical data, as it is in Hebrew and google fails to translate it. Maybe you will have less problems.
I found some datasets from Israel.
https://data.gov.il/dataset/covid-19
May be they are the ones you were looking for.
As for rest: I'd say ~60% protection against infection by delta using vaccine against original strain is pretty good, considering that original criterium for vaccine was 50% protection against hospitalization.
Looking at my corner of Republic (Královehradecký kraj), we're doing pretty good... (But then, we were ran over by Covid in winter)
But I do see where are you coming from.
Originally Posted by
marting
Here's recent study in Nature (Nov. 2) That shows Ve against infection around 50%
https://www.nature.com/articles/s41591-021-01583-4
BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0–61.6%) ≥14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0–56.4%) ≥14 d after the second dose, with 50% of fully vaccinated individuals receiving their second dose before 11 May 2021.
Lancet Preprint. Consistent with the Nature piece above.
Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study
https://papers.ssrn.com/sol3/papers....act_id=3949410
Findings: Vaccine effectiveness of BNT162b2 against infection waned progressively from 92% (95% CI, 92-93, P<0·001) at day 15-30 to 47% (95% CI, 39-55, P<0·001) at day 121-180, and from day 211 and onwards no effectiveness could be detected (23%; 95% CI, -2-41, P=0·07).
Hm, I would ignore that last part about no protection. P-value is high. (Null hypothesis cannot be dismissed)
But then there is this French study:
https://www.epi-phare.fr/app/uploads...s_50_74ans.pdf
Although it seems they were more interested in hospitalizations.
From brief search there don't seem top be any other studies of similar nature. (And I can't use more time into this)